Download our case study to:

Delve into how TFS leveraged vast US real-world data to secure EMA approval for an extended-release CNS drug, bypassing traditional costly trials.

Witness how our RWE team’s innovative design and AI-assisted analyses cut costs by 30 times and accelerated timelines, achieving non-inferiority and even superiority in key endpoints. Download now to uncover the RWE-driven breakthroughs that delivered this triumph.

Learn more about our related services and resources:

Phase IV-RWE

Learn More About Our Real World Evidence Expertise